Company intelligence
Regenerative Medicine Solutions
Hospitals
Barcelona, ES
2 employees
4 public signals
Verified activity
Signals from Regenerative Medicine Solutions
4 published signals
Research & Knowledge
Regenerative Medicine Solutions published a study in Science by A. J. Wesolowski et al. (2026) showing that mouse tumors release the enzyme peroxiredoxin 1 (PRDX1) into the interstitial fluid to remove H2O2 near T cells, which weakens T cell receptor signaling.
Reported by Miguel Bronchud
Research & Knowledge
Regenerative Medicine Solutions published a study of more than 72,000 people showing that those who received the latest shingles vaccine have a lower risk of stroke or heart failure compared to older versions.
Reported by Miguel Bronchud
Research & Knowledge
Regenerative Medicine Solutions did not claim any business signals about the author's company, but the post discusses a longitudinal single-cell RNA sequencing atlas assembled by Israeli and German researchers for Translational Skin Cancer Research and the German Cancer Consortium.
Reported by Miguel Bronchud
Research & Knowledge
Regenerative Medicine Solutions published a study by Freedland et al (2026) in the journal Cancer indicating that reaching a prostate-specific antigen level below 0.2 ng/mL is an indicator of improved patient survival in metastatic castration-sensitive prostate cancer patients.
Reported by Miguel Bronchud